24
Participants
Start Date
March 31, 2016
Primary Completion Date
September 30, 2017
Study Completion Date
December 31, 2018
humanized anti-PD-1 monoclonal antibody toripalimab
humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
Sun Yat-sen UniversityCancer center, Guangzhou
Shanghai Junshi Bioscience Co., Ltd.
OTHER